Kornimate/medical-research-clean huggingface dataset:
gnrh agonist pretreatment in hysteroscopic myomectomy

Conditions: Uterine Myoma

Summary: the primary outcome of this study is to assess if the gnrha administration before cold loop hysteroscopic myomectomy contributes to accomplish the treatment in only one surgical procedure. moreover, we will investigate the intraoperative influence of such pharmacologic therapy in terms of distension liquid absorption and duration of the procedures.


Eligibility criteria:
inclusion criteria: * submucous myoma diagnosed by vaginal ultrasonography and confirmed by diagnostic hysteroscopy * premenopausal status exclusion criteria: * present or past history of cancer * pregnancy * presence of associated multiple polyps * presence of \> 2 myomas * associated nonhysteroscopic surgical procedures

Keywords: uterine myoma gnrha hysteroscopy cold loop
etoposide in treating patients with advanced ovarian or cervical cancer

Conditions: Cervical Cancer; Ovarian Cancer

Summary: rationale: drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. purpose: phase ii trial to study the effectiveness of etoposide in treating patients who have refractory, recurrent, or metastatic ovarian or cervical cancer.

objectives: i. determine the efficacy of prolonged oral etoposide (vp-16) in patients with advanced ovarian epithelial or cervical cancer. ii. evaluate the frequency and severity of observed adverse effects in this patient population treated with prolonged oral vp-16. outline: patients receive etoposide by mouth once daily on days 1-21 every 4 weeks. patients with responding disease continue treatment for up to 12 months in the absence of disease progression or unacceptable toxicity. patients with stable disease continue treatment for up to 6 months in the absence of disease progression or unacceptable toxicity. projected accrual: if 4-6 responses are observed in the first 25 patients, an additional 15 patients will be entered. the estimated duration of the study is 8 months.

Eligibility criteria:
disease characteristics: histologically confirmed recurrent or metastatic ovarian epithelial or cervical cancer tissue not accessible for biopsy refractory to curative therapy or established treatments and ineligible for higher priority gog protocols measurable disease required, as follows: lesion measurable by physical exam lesion bidimensionally measurable on sonogram or imaging ascites/pleural effusion not measurable patient characteristics: age: any age performance status: gog 0-2 hematopoietic: wbc at least 3,000/mm3 absolute granulocyte count at least 1,500/mm3 platelets at least 100,000/mm3 hepatic: bilirubin no more than 1.5 times normal ast no more than 3 times normal alkaline phosphatase no more than 3 times normal renal: creatinine no greater than 2.0 mg/dl other: body surface area at least 1 square meter no requirement for intravenous hydration or nutritional support no significant infection no second malignancy other than nonmelanomatous skin cancer prior concurrent therapy: biologic therapy: at least 3 weeks since anticancer therapy chemotherapy: no more than 1 prior chemotherapy trial no prior etoposide at least 3 weeks since chemotherapy and recovered endocrine therapy: at least 3 weeks since anticancer therapy radiotherapy: at least 3 weeks since radiotherapy surgery: at least 3 weeks since surgery and recovered

Keywords: recurrent cervical cancer recurrent ovarian epithelial cancer
evaluation of academic and professional trajectories of narcoleptic patients

Conditions: Narcolepsy

Summary: narcolepsy is a chronic, disabling condition characterized by excessive daytime sleepiness and, in some patients, falls in muscle tone related to emotions (cataplexies). it often begins in childhood or in young adults. symptoms of narcolepsy are responsible for an important handicap in everyday life, and are often misunderstood by the family and professional environment. in addition, many comorbidities are associated with narcolepsy, such as depression, anxiety, or obesity. few studies have examined the impact of narcolepsy on patients' educational background, socio-professional integration, and quality of life. in particular, the factors of professional handicap related to the characteristics of the disease and the determinants of the insertion of the patients remain poorly known. as a better understanding of these determinants could help to inform patients and guide them in their choices, narcowork study aims at evaluating the academic and professional trajectories of a wide population of narcoleptic patients.


Eligibility criteria:
inclusion criteria: group "narcoleptic patients": * type 1 or type 2 narcolepsy * \> 18 years * usually followed at the lyon sleep medicine center group "control": * at least one member of each family of cases (siblings, cousins ...) * \> 18 years and of the same age as the case if possible (+/- 5 years) * no narcolepsy exclusion criteria: * uncertain diagnosis (for the "narcoleptic patients" group) * poor knowledge of the french language * refusal to participate
exhaled nitric oxide and nasal lavage fluid

Conditions: Asthma

Summary: the allergic respiratory diseases such as asthma or allergic rhinitis are the main chronic diseases in children. the airway inflammation plays an important role in their pathophysiology. several epidemiological studies show that environmental tobacco smoke (ets) exacerbates the symptoms of asthma and allergies. the aim of this study is to assess the impact of environmental tobacco smoke on the measurement of exhaled nitric oxide (eno) and biomarkers of nasal inflammation in atopic asthmatic children.

type of study : this study is a epidemiological observation study type exposed or unexposed to environmental tobacco smoke. methods : the eno is determined by a method on-line, at a rate expiratory 50 ml / s, using a chemiluminescence no analyzer, before the allergy assessment (skin tests and assay of serum total and specific ige ) and measurement of lung function (spirometry). nasal lavage is performed by using a validated technique . cells are counted and differentiated after giemsa staining. we measured 1-anti-trypsin, neutrophil elastase, albumin, urea, il4 , il6, il8 and il13. exposure to ets is assessed by questionnaire to the parents. statistical analysis include a narrative strand to verify the normality of distribution and an analytical analysis, including a bivariate followed by a multivariate analysis by multiple linear regression and / or logistic regression to model concentrations of biomarkers of inflammation and adjustment variables such as age, sex, atopic status, eosinophilia and severity of asthma.

Eligibility criteria:
inclusion criteria: * aged over 5 years * atopic, persistent mild and moderate asthmatic children (gina 2 and 3) exclusion criteria: * child with asthma medication asthma used in the previous 15 days (oral or inhaled corticosteroids, leukotriene antagonist) * recent asthma attack (day of hospitalization or 15 days earlier) * upper respiratory infection (4 weeks) and low (2 weeks) * active smoking (teenager)

Keywords: children tobacco smoke exposure exhaled nitric oxide nasal lavage cytokines
health-related quality of life and disease-related costs: comparison between ankylosing spondylitis, rheumatoid arthritis and systemic lupus erythematosus in taiwan

Conditions: Rheumatoid Arthritis; Systemic Lupus Erythematosus; Ankylosing Spondylitis

Summary: ankylosing spondylitis (as), rheumatoid arthritis (ra) and systemic lupus erythematosus (sle) are the most common rheumatic diseases dealt with rheumatologists in taiwan. in previous studies, the 3 diseases all have broad impacts on health-related quality of life of patients and drive enormous economic burden on patients and society. the objective of this study is to compare health-related quality of life and disease-related costs between patients with the 3 different diseases. we will invite at least 100 patients with as, ra or sle respectively who are regularly followed in the outpatient clinic of the division of rheumatology at taichung veterans general hospital (vghtc) to participate in the study. patients who have cognitive impairment, who are older than 65 years old or younger than 18 years old, who have overlapping syndrome of any 2 of the 3 rheumatic diseases (eg. ra overlapping with sle) or who have visited rheumatologists in the outpatient clinics at vghtc for less than 4 times in 2008 will be excluded. patients who agree to take part will attend a comprehensive clinical examination in the outpatient department. patients will complete a questionaire including demographic and disease characteristics, and health-related quality of life at the time of survey. the questionaires about disease-related costs will be completed once per quarter throughout 2009. the four questionaires about costs will be given at the time of initial survey and will be returned by returned by mail or in the following outpatient clinics visits every 3 months in 2009. the result of this study will help patients to realize their own health-related quality of life and disease-related costs and help government in taiwan to realize the socioeconomic burden of the 3 common rheumatic diseases and to allocate health care resources more properly in the future.


Eligibility criteria:
inclusion criteria: * as patients who fit the modified new york criteria (1984) * ra patients who fit the american college of rheumatology (acr) criteria (1987) * sle patients who fit the acr revised criteria for the classification of sle (1997) exclusion criteria: * 1. patients who have cognitive impairment. * 2. patients who have overlapping syndrome of any 2 of the 3 rheumatic disease (eg. ra overlapping with sle). * 3. patients who are less than 18 years old or older than 65 years old. * 4. patients who visited rheumatologists in the outpatient clinics of the division of rheumatology at taichung veterans general hospital for less than 4 times in 2008.

Keywords: ankylosing spondylitis (as), costs, rheumatoid arthritis (ra), systemic lupus erythematosus (sle), health-related quality of life (hrqol) compare utility patients
a single ascending dose trial of cvl-936 in healthy subjects

Conditions: Substance Use Disorders (SUD)

Summary: the aim of this trial is to investigate the safety, tolerability, pharmacokinetics (pk), and pharmacodynamics (pd) of cvl-936 following single ascending oral doses in healthy subjects.


Eligibility criteria:
inclusion criteria: 1. healthy male subjects and female subjects of nonchildbearing potential, ages 18 to 50 years exclusion criteria: 1. subjects with a current history of significant pulmonary, gastrointestinal, renal, hepatic, metabolic, endocrine, hematological, immunological, psychiatric, or neurological disease that, in the opinion of the investigator or medical monitor, could compromise either subject safety or the results of the trial. 2. subjects with epilepsy or a history of seizures 3. systolic supine blood pressure ≥130 mmhg and/or supine diastolic blood pressure ≥80 mmhg at screening or day -1, or orthostatic hypotension at screening or day -1. 4. subjects with a history of hypersensitivity to any dopamine-blocker medication.
hospital onset diarrhoea investigation

Conditions: Diarrhea

Summary: this service evaulation aims to investigate how common diarrhoea is in hospital patients on medical, surgical and elderly care wards, what it is due to and how it is managed.

latest national health service (nhs) england guidelines for the assessment of clostridium difficile infection (cdi) cases recommend that acute hospitals collect data on the prevalence of hospital-onset diarrhoea in their organisations, and how it is managed, including if patients are appropriately tested for cdi. the aims of this multi-centre service evaluation are therefore to: * determine the prevalence of hospital-onset diarrhoea on adult medical, surgical and care of the elderly wards in the nhs * investigate how hospital-onset diarrhoea is managed, including whether patients are tested for cdi according to department of health (doh) england standards * investigate the aetiology of hospital-onset diarrhoea on adult medical, surgical and care of the elderly wards in the nhs, based on previously described causes data will be collected at participating centres on two days, one between 11-15/jan/2016 and one between 6-10/jun/2016. hospitals will be able to choose locally which two days. on those days investigators from the local microbiology and/or infection prevention teams will screen all patients on pre-identified wards, who have been admitted for ≥72 hours, for hospital-onset diarrhoea. for all patients that meet the definition of hospital-onset diarrhoea their medical notes and charts will be reviewed, to ascertain potential causes and how they have been managed. this service evaluation should help participating hospitals to investigate hospital-onset diarrhoea in their own institutions, as well as generating a dataset that is representative of the problem across the nhs, and therefore of use to other centres.

Eligibility criteria:
inclusion criteria: * admitted to hospital for ≥72 hours at the time of data collection for the service evaluation * presence of hospital-onset diarrhoea (defined as ≥ 2 episodes of unformed stools (bristol stool chart type 5-7) during the day before the service evaluation, with the onset of the diarrhoea being more than 48 hours after admission to hospital) exclusion criteria: * patients admitted to the ward for ≤72hour at the time of data collection for the service evaluation * patients with diarrhoea since admission or in whom it developed within the first 48 hours of admission * patients receiving end of life care

Keywords: nosocomial hospital acquired clostridium difficile
association of sleep quality with pathologic staging, acupuncture treatment in patients with chronic atrophic gastritis: a cross-sectional study

Conditions: Chronic Atrophic Gastritis (CAG)

Summary: in order to inform clinical treatment decisions and maximize treatment outcomes, this observational study set out to examine the relationship between pathological severity and sleep quality in patients with cag. the idea that "if the stomach is not in harmony, you will be restless" is supported by this evidence from traditional chinese medicine. assessing patients' knowledge and acceptance of acupuncture therapy, determining the current general trend in cag treatment, and assessing the initial effectiveness of acupuncture therapy in treating cag with sleep disturbances. it is envisaged that the aforementioned investigations will aid in further refining the clinical research strategy of acupuncture and moxibustion with cag with sleep disorders, enhance the effectiveness of treatment, and offer a more cost-effective and practical choice for treating cag with sleep disorders. the primary research issue is: can the traditional chinese medical notion of "restlessness due to disharmony of the stomach" be validated in order to ascertain whether there is a correlation between pathological severity and sleep quality in patients with chronic atrophic gastritis? the pathological conditions of cag patients were gathered based on the most recent gastroscopy report within a year, and the patients' sleep quality scores from the previous month were gathered via a questionnaire.

this is a single-center, cross-sectional study

Eligibility criteria:
inclusion criteria: 1. have been diagnosed with chronic atrophic gastritis; 2. be between the ages of 18 and 75, with no restrictions on gender; 3. read the informed consent form, sign it, and consent to participate in this study. exclusion criteria: 1. autoimmune gastritis (chronic atrophic gastritis type a); 2. patients with gastroesophageal reflux disease (gerd) as determined by endoscopy or other examinations, or patients with high-grade intraepithelial neoplasia pathologically as determined by upper gastrointestinal endoscopy and gastric mucosal biopsy; 3. patients with confirmed or unexcluded malignant tumors, particularly esophageal and gastric cancer;patients with other upper gastrointestinal pathologies, such as barrett's esophagus or peptic ulcer; 4. additional physical, mental, psychological, or pathological conditions that may impact sleep scores, such as the use of medications for insomnia, night shifts, jet lag, major events, severe neurosis, menopausal syndrome, uncontrolled hyperthyroidism, severe diabetic peripheral neuropathy, within a month after surgical trauma, etc. 5. people who use medicines that can make you sleepy at the same time and stop using them for less than a month; 6. people who can't finish the questionnaire because they're unconscious, can't talk regularly, or have other issues; people who don't have enough information.

Keywords: chronic atrophic gastritis; sleep quality; olga; olgim; pathologic; acupuncture; cross-sectional
trial to study the effects of supplementary omega-3 on serum c-reactive protein levels

Conditions: Coronary Artery Disease; Inflammatory Response; Atherosclerosis

Summary: to study the anti-inflammatory effects of marine omega-3 fatty acids, also known as n-3 polyunsaturated fatty acids (pufa), we propose a randomized, double-blinded, prospective, single-center trial to examine the effect of supplementary n-3 pufa on serum high sensitivity (hs) crp levels. inclusion criteria age \> 18 hs crp \>3mg/l and \<10 mg/l exclusion criteria active infection systemic inflammatory disease autoimmune disorders systemic lupus erythematosus (sle) rheumatoid arthritis (ra) systemic sclerosis (scleroderma) sjögren's syndrome behçet's syndrome the vasculitis syndromes including: wegener's granulomatosis temporal arteritis (giant cell arteritis) takayasu's arteritis henoch-schönlein purpura predominantly cutaneous vasculitis (hypersensitivity vasculitis) sarcoidosis amyloidosis currently on warfarin cr \> 2.0 fish allergy pregnancy or unwillingness to use some form of birth control in women of child-bearing age during the 8 weeks. we will enroll 200 pts. at willoughby hills family health center over a 2 month period 100 pts. will receive omega-3, 100 pts. will receive placebo drug is to be taken over 8 weeks pt. will return to willoughby hills in 8 weeks for a follow-up hscrp. a brief questionnaire will be completed by the nurse/pt, including vital signs at baseline and follow-up . primary outcome: hscrp levels after 8 weeks of treatment with pufa

all patients will be given an 8 week supply of placebo or study drug. the exact composition of both the active drug and placebo is detailed below. the physician and the patient will both be blinded. patients will be instructed to take three capsules daily in the morning. each capsule of the drug contains 450 mg of eicosapentaenoic acid (epa), the active component. thus, three capsules daily will result in 1350 mg daily of epa. they will be asked to return to the clinic after 8 weeks of therapy for a follow-up hscrp. patients: healthy patients seen in a primary care setting at the department of internal medicine at the cleveland clinic health system willoughby satellite. drug: active arm: 1000 mg lemon flavored capsules. three capsules every morning. fill 45% eicosapentaenoic acid 10% docosahexaenoic acid 10% combined total of docopentaneoic acid and alfa-linoleic acid natural lemon oil rosemary liquid extract d-alpha tocopherol vitamin e (67.1% w/w) (1000iu/g) antioxidants, proprietary mix shell gelatin glycerol purified water lemon oil placebo arm: cornstarch capsules provided by clinical encapsulation services. three capsules every morning.

Eligibility criteria:
inclusion criteria: * age \> 18 * hs crp \>3mg/l and \<10 mg/l exclusion criteria: * active infection * systemic inflammatory disease * currently on warfarin * cr \> 2.0 * fish allergy * pregnancy or unwillingness to use some form of birth control

Keywords: omega3 fatty acids hscrp cad
deprescribing of diabetes regimens in long term care residents with alzheimer's

Conditions: Diabetes; Dementia; Hypoglycemia; Drug

Summary: objectives to 1) examine the ability of the stride (simplification of treatment regimens and individualized diabetes education) educational program to increase deprescribing of high hypoglycemia risk glucose-lowering medications (hrms) among long term care facility (ltcf) residents with adrd, 2) assess key implementation constructs (secondary outcomes) of the stride program, including acceptability, appropriateness, and feasibility, and 3) validate the primary hrm use outcome measure.


Eligibility criteria:
inclusion criteria: * clinical staff at the ltcf (mds, pas, nps, clinical pharmacists) - (targeted providers for stride program) * clinical staff that participated in the stride program (providers doing stakeholder exit interviews) exclusion criteria: * consistent with the pragmatic nature of the trial, there are no exclusion criteria.

Keywords: older adults long term care facility high risk medications hypoglycemia deprescribing diabetes dementia
nocturnal oxygen treatment in heart failure and cheyne-stokes respiration

Conditions: Heart Failure

Summary: the purpose of this study is to determine whether oxygen therapy during sleep improves quality of life, exercise capacity and heart function among patients with chronic heart failure and central sleep apnea.

oxygen therapy reduces the number of central apneas among patients with congestive heart failure but it is unknown whether quality of life and heart function also improve. we aim to test whether the quality of life, exercise capacity and heart function are improved with nocturnal oxygen therapy during 6 weeks with nocturnal oxygen from oxygen concentrator or nocturnal air from placebo concentrator.

Eligibility criteria:
inclusion criteria: * stable heart failure with left ventricular dysfunction * cheyne-stokes respiration with central ahi\>15 and obstructive ahi\<5 exclusion criteria: * heart infarction within 3 months. * dementia * chronic obstructive pulmonary disease and daytime hypoxemia.